PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
13.12%
Revenue growth similar to ADI's 13.81%. Walter Schloss would see if both companies share industry tailwinds.
16.17%
Gross profit growth at 75-90% of ADI's 19.60%. Bill Ackman would demand operational improvements to match competitor gains.
10.22%
EBIT growth below 50% of ADI's 35.14%. Michael Burry would suspect deeper competitive or cost structure issues.
12.17%
Operating income growth under 50% of ADI's 35.14%. Michael Burry would be concerned about deeper cost or sales issues.
13.43%
Net income growth under 50% of ADI's 34.07%. Michael Burry would suspect the firm is falling well behind a key competitor.
8.33%
EPS growth under 50% of ADI's 31.25%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
8.70%
Diluted EPS growth under 50% of ADI's 33.33%. Michael Burry would worry about an eroding competitive position or excessive dilution.
2.53%
Share count expansion well above ADI's 1.14%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.38%
Diluted share count expanding well above ADI's 2.04%. Michael Burry would fear significant dilution to existing owners' stakes.
0.49%
Dividend growth of 0.49% while ADI is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
83.58%
OCF growth above 1.5x ADI's 34.62%. David Dodd would confirm a clear edge in underlying cash generation.
152.78%
FCF growth above 1.5x ADI's 31.25%. David Dodd would verify if the firm’s strategic investments yield superior returns.
12.26%
10Y revenue/share CAGR under 50% of ADI's 216.31%. Michael Burry would suspect a lasting competitive disadvantage.
-16.56%
Negative 5Y CAGR while ADI stands at 185.35%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
101.94%
3Y revenue/share CAGR 1.25-1.5x ADI's 90.02%. Bruce Berkowitz might see better product or regional expansions than the competitor.
153.21%
10Y OCF/share CAGR under 50% of ADI's 472.75%. Michael Burry would worry about a persistent underperformance in cash creation.
94.23%
Below 50% of ADI's 208.20%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
34.58%
3Y OCF/share CAGR under 50% of ADI's 361.73%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
882.41%
Below 50% of ADI's 11812.66%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
108.68%
Below 50% of ADI's 353.93%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
1537.14%
3Y net income/share CAGR above 1.5x ADI's 123.44%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
188.07%
10Y equity/share CAGR at 50-75% of ADI's 261.85%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
162.02%
5Y equity/share CAGR at 50-75% of ADI's 316.67%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
99.34%
3Y equity/share CAGR at 50-75% of ADI's 151.55%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
10.49%
Dividend/share CAGR of 10.49% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
27.18%
Dividend/share CAGR of 27.18% while ADI is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
-6.24%
Negative near-term dividend growth while ADI invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-5.96%
Firm’s AR is declining while ADI shows 6.12%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
18.73%
We show growth while ADI is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
13.87%
Asset growth above 1.5x ADI's 6.85%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
13.93%
BV/share growth above 1.5x ADI's 5.18%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-0.91%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-3.71%
Our R&D shrinks while ADI invests at 12.37%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
28.49%
SG&A growth well above ADI's 9.34%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.